Abstract
Distal myopathies are a group of rare, inherited muscular disorders characterized by progressive loss of muscle fibers that begins in the distal parts of arms and legs. Recently, variants in a new disease gene, ACTN2, have been shown to cause distal myopathy. ACTN2, a gene previously only associated with cardiomyopathies, encodes alpha-actinin-2, a protein expressed in both cardiac and skeletal sarcomeres. The primary function of alpha-actinin-2 is to link actin and titin to the sarcomere Z-disk. New ACTN2 variants are continuously discovered, however, the clinical significance of many variants remains unknown. Thus, lack of clear genotype-phenotype correlations in ACTN2-related diseases, actininopathies, persists.
Objective The objective of the study is to characterize the pathomechanisms underlying actininopathies.
Methods Functional characterization in C2C12 cell models of several ACTN2 variants is conducted, including frameshift and missense variants associated with dominant actininopathies. We assess the genotype-phenotype correlations of actininopathies using clinical data from several patients carrying these variants.
Results The results show that the missense variants associated with a recessive form of actininopathy do not cause detectable alpha-actinin-2 aggregates in the cell model. Conversely, dominant frameshift variants causing a protein extension do produce alpha-actinin-2 aggregates.
Interpretation The results suggest that alpha-actinin-2 aggregation is the disease mechanism underlying some dominant actininopathies, and thus we recommend that protein-extending frameshift variants in ACTN2 should be classified as pathogenic. However, this mechanism is likely elicited by only a limited number of variants. Alternative functional characterization methods should be explored to further investigate other molecular mechanisms underlying actininopathies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Folkhalsan Research Foundation (to MS and BU), the Jane and Aatos Erkko Foundation (BU), the Sigrid Juselius Foundation (MS and BU), Finska Lakaresallskapet (BU), Association Francaise contre les Myopathies (grant #23281 to MS), Academy of Finland (grant #339437 to MS), European Joint Programme for Rare Disease (BU), and Sydantutkimussaatio (MS). Sequencing and analysis of Family A were provided by the Broad Institute of MIT and Harvard Center for Mendelian Genomics (Broad CMG) and were funded by the National Human Genome Research Institute grants UM1 HG00890 (with additional support from the National Eye Institute, and the National Heart, Lung and Blood Institute), U01 HG0011755, and R01 HG00914 and in part by CZI grant DAF2019-199278 and grant DOI https://doi.org/10.37921/236582yuakxy from the Chan Zuckerberg Initiative DAF, an advised fund of Silicon Valley Community Foundation (funder DOI 10.13039/100014989).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The institutional review board of Helsingin yliopistollinen sairaala Hospital District of Helsinki and Uusimaa (HUS:195/13/03/00/11) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
8 Data Availability
The data that supports the findings of this study are being shared or are available in Leiden Open Variation Database at https://databases.lovd.nl/shared/genes/ACTN2 and in ClinVar (National Library of Medicine, National Institute of Health) https://www.ncbi.nlm.nih.gov/clinvar/?term=ACTN2[gene].
